Sanara MedTech Inc. (SMTI)

[SPM555]

10q released: Wound Management Technologies, Inc. is pleased to report second quarter 2018 revenue of $2,262,090 which was up 56% compared to prior year and represented an all-time high in quarterly sales for the Company. The higher revenues were the result of our continued success implementing strategic initiatives to grow our sales force, expand our surgical product sales to new customers, and a renewed focus on long-term care. We are also increasing our market presence with continuing case studies by key opinion leaders.

The Company also achieved another profitable quarter, as it continues to invest heavily in expanding its sales reach, product development and clinical support. All convertible debt was converted to common shares of the Company's stock in the first quarter of 2018, resulting in zero debt on the balance sheet for the first time in the history of the Company. In addition, all Series C Convertible Preferred Stock shareholders converted their Series C shares and related dividends to common shares of the Company's stock resulting in one class of common shares issued and outstanding as of March 31, 2018 .

In closing, Wound Management Technologies continues to be well positioned to execute our strategic growth initiatives with a solid go-to-market plan in place. The Company looks forward to capitalizing on the traction it has built in the market thus far with additional investments in strategic growth, sales, marketing and clinical support for CellerateRX/CRX? Activated Collagen/CRX? Adjuvant and HemaQuell Resorbable Bone Hemostat.

http://archive.fast-edgar.com//20180813/A3AYWG2CZ222UZZZ2M2O2ZZI2OOVZS22Z2A2/